Clinical Trials with Glycoprotein IIb/IIIa Receptor Antagonists in Acute Coronary Syndromes

Overview

Journal Thromb Haemost

Publisher Thieme

Specialties Cardiology & Vascular Diseases
Hematology

Date 1997 Jul 1

PMID 9198155

Citations 7

Authors

F Van de Werf

Affiliations

Soon will be listed here.

Abstract

Glycoprotein IIb/IIIa receptor antagonists are more potent platelet inhibitors than aspirin. Although important reductions in ischemic/thrombotic complications have been observed with these agents following coronary interventions, their potential value for the medical treatment of acute coronary syndromes is at present uncertain. The final results of large randomized studies in patients with acute coronary syndromes are eagerly awaited.

Citing Articles

Pharmacosimulation of delays and interruptions during administration of tirofiban: a systematic comparison between EU and US dosage regimens.

Heramvand N, Masyuk M, Muessig J, Nia A, Karathanos A, Polzin A J Thromb Thrombolysis. 2022; 54(2):301-308.

PMID: 35482154 PMC: 9363357. DOI: 10.1007/s11239-022-02654-0.

Role of fibrin D-dimer testing in emergency medicine.

Wakai A, Gleeson A, Winter D Emerg Med J. 2003; 20(4):319-25.

PMID: 12835339 PMC: 1726151. DOI: 10.1136/emj.20.4.319.

New advances in the management of acute coronary syndromes: 4. Low-molecular-weight heparins.

Ageno W, Turpie A CMAJ. 2002; 166(7):919-24.

PMID: 11949991 PMC: 100928.

Arterial indications for the low molecular weight heparins.

Ageno W, Huisman M Curr Control Trials Cardiovasc Med. 2002; 2(5):233-239.

PMID: 11806802 PMC: 59526. DOI: 10.1186/cvm-2-5-233.

Eptifibatide: a review of its use in patients with acute coronary syndromes and/or undergoing percutaneous coronary intervention.

Goa K, Noble S Drugs. 1999; 57(3):439-62.

PMID: 10193692 DOI: 10.2165/00003495-199957030-00015.